SELECT

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.

17 604

Schéma

Double-blind RCT

Critère

CV death, MI or stroke

Pertinence

Résultat6.5 % vs 8.0 % (HR 0.80); mean weight loss 9.4 %.

Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232. 10.1056/NEJMoa2307563

Discussion et critique

First trial to show cardiovascular risk reduction from treating obesity itself, without diabetes. How much of the benefit is weight loss versus direct drug effect is unresolved.